



Clinical trial results:

An Open-label, Multicenter Follow-up Study to Collect Long-term Data on Participants from Multiple Bintrafusp alfa (M7824) Clinical Studies Summary

EudraCT number	2021-000179-36
Trial protocol	FR BE ES IT DE
Global end of trial date	21 March 2025

Results information

Result version number	v1 (current)
This version publication date	06 March 2026
First version publication date	06 March 2026

Trial information

Trial identification

Sponsor protocol code	MS200647_0054
-----------------------	---------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT05061823
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Merck Healthcare KGaA, Darmstadt Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Sponsor organisation address	Frankfurter Strasse 250, Darmstadt, Germany, 64293
Public contact	Communication Center, Merck Healthcare KGaA, Darmstadt Germany, an affiliate of Merck KGaA, Darmstadt, Germany, +49 6151725200, service@emdgroup.com
Scientific contact	Communication Center, Merck Healthcare KGaA, Darmstadt Germany, an affiliate of Merck KGaA, Darmstadt, Germany, +49 6151725200, service@emdgroup.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	21 March 2025
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	21 March 2025
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

This study was designed to provide continuous access to treatment with bintrafusp alfa for eligible subjects from ongoing bintrafusp alfa parent studies (NCT02517398, NCT02699515, NCT04246489, NCT03840915, NCT03631706, NCT04551950, NCT03833661 and NCT04066491) and to collect long-term safety and efficacy data.

Study Duration: All subjects in this rollover study will be treated with bintrafusp alfa until meeting defined criteria in the protocol for discontinuation, until study intervention is commercially accessible and provisioned via marketed product, or until end of study.

The study also includes a 5 years survival follow-up after last dose of the study treatment.

Treatment Duration: Treatment under the rollover protocol according to the interval and dosing schedule in the parent protocol until discontinuation.

Protection of trial subjects:

Subject protection was ensured by following high medical and ethical standards in accordance with the principles laid down in the Declaration of Helsinki, and that are consistent with Good Clinical Practice and applicable regulations.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	01 December 2021
Long term follow-up planned	Yes
Long term follow-up rationale	Safety
Long term follow-up duration	5 Years
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Spain: 2
Country: Number of subjects enrolled	Russian Federation: 1
Country: Number of subjects enrolled	Belgium: 1
Country: Number of subjects enrolled	Taiwan: 2
Country: Number of subjects enrolled	Türkiye: 1
Country: Number of subjects enrolled	China: 1
Country: Number of subjects enrolled	Ukraine: 2
Country: Number of subjects enrolled	Japan: 3
Country: Number of subjects enrolled	Korea, Democratic People's Republic of: 9
Country: Number of subjects enrolled	United States: 1
Worldwide total number of subjects	23
EEA total number of subjects	3

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	16
From 65 to 84 years	7
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

A total of 23 subjects consented for the rollover study.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Biliary Tract Cancer

Arm description:

Subjects with biliary tract cancer, who were continuing treatment with bintrafusp alfa and were previously assigned to a bintrafusp alfa dose based on body weight (i.e., milligrams per kilogram (mg/kg) dose) in a parent protocol (NCT02517398, NCT02699515, NCT04246489, NCT03840915, NCT03631706, NCT04551950, NCT03833661, and NCT04066491), received an intravenous infusion of bintrafusp alfa at the dose specified based upon the subjects parent protocol once every 2 weeks or 2400 mg once every 3 weeks until disease progression, death, unacceptable toxicity, or study withdrawal. Subjects who entered the rollover study after discontinuation of treatment in a parent study received bintrafusp alfa at a dose of either 1200 or 2400 mg once every 2 weeks or 2400 mg once every 3 weeks until disease progression, death, unacceptable toxicity, or study withdrawal.

Arm type	Experimental
Investigational medicinal product name	Bintrafusp alfa
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects who are continuing treatment with bintrafusp alfa and were previously assigned to a bintrafusp alfa dose based on body weight which is (i.e.) milligrams per kilogram (mg/kg) dose in a parent protocol, received an intravenous infusion of bintrafusp alfa at the dose specified based upon the subject's parent protocol once every 2 week or, 2400 mg once every 3 weeks. Subjects who are entering the rollover study after discontinuation of treatment in a parent study received bintrafusp alfa at a dose of either 1200 or 2400 mg once every 2 weeks or 2400 mg once every 3 weeks until confirmed disease progression, death, unacceptable toxicity or study withdrawal.

Arm title	Non-small Cell Lung Cancer
------------------	----------------------------

Arm description:

Subjects with Non small cell lung cancer, who were continuing treatment with bintrafusp alfa and were previously assigned to a bintrafusp alfa dose based on body weight i.e., mg/kg dose in a parent protocol (NCT02517398, NCT02699515, NCT04246489, NCT03840915, NCT03631706, NCT04551950, NCT03833661, and NCT04066491), received an intravenous infusion of bintrafusp alfa at the dose specified based upon the subjects parent protocol once every 2 weeks or 2400 mg once every 3 weeks until disease progression, death, unacceptable toxicity, or study withdrawal. Subjects who entered the rollover study after discontinuation of treatment in a parent study received bintrafusp alfa at a dose of either 1200 or 2400 mg once every 2 weeks or 2400 mg once every 3 weeks until disease progression, death, unacceptable toxicity, or study withdrawal.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Bintrafusp alfa
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects who are continuing treatment with bintrafusp alfa and were previously assigned to a bintrafusp alfa dose based on body weight which is (i.e.) milligrams per kilogram (mg/kg) dose in a parent protocol, received an intravenous infusion of bintrafusp alfa at the dose specified based upon the subject's parent protocol once every 2 week or, 2400 mg once every 3 weeks. Subjects who are entering the rollover study after discontinuation of treatment in a parent study received bintrafusp alfa at a dose of either 1200 or 2400 mg once every 2 weeks or 2400 mg once every 3 weeks until confirmed disease progression, death, unacceptable toxicity or study withdrawal.

Arm title	Cervical Cancer
------------------	-----------------

Arm description:

Subjects with cervical cancer, who were continuing treatment with bintrafusp alfa and were previously assigned to a bintrafusp alfa dose based on body weight i.e., mg/kg dose in a parent protocol (NCT02517398, NCT02699515, NCT04246489, NCT03840915, NCT03631706, NCT04551950, NCT03833661, and NCT04066491), received an intravenous infusion of bintrafusp alfa at the dose specified based upon the subject's parent protocol once every 2 weeks or 2400 mg once every 3 weeks until disease progression, death, unacceptable toxicity, or study withdrawal. Subjects who entered the rollover study after discontinuation of treatment in a parent study received bintrafusp alfa at a dose of either 1200 or 2400 mg once every 2 weeks or 2400 mg once every 3 weeks until disease progression, death, unacceptable toxicity, or study withdrawal.

Arm type	Experimental
Investigational medicinal product name	Bintrafusp alfa
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects who are continuing treatment with bintrafusp alfa and were previously assigned to a bintrafusp alfa dose based on body weight which is (i.e.) milligrams per kilogram (mg/kg) dose in a parent protocol, received an intravenous infusion of bintrafusp alfa at the dose specified based upon the subject's parent protocol once every 2 week or, 2400 mg once every 3 weeks. Subjects who are entering the rollover study after discontinuation of treatment in a parent study received bintrafusp alfa at a dose of either 1200 or 2400 mg once every 2 weeks or 2400 mg once every 3 weeks until confirmed disease progression, death, unacceptable toxicity or study withdrawal.

Arm title	Other (Colorectal cancer, Glioblastoma, Melanoma)
------------------	---

Arm description:

Subjects with Other (Colorectal cancer, Glioblastoma, Melanoma) who were continuing treatment with bintrafusp alfa and were previously assigned to a bintrafusp alfa dose based on body weight i.e., mg/kg dose in a parent protocol (NCT02517398, NCT02699515, NCT04246489, NCT03840915, NCT03631706, NCT04551950, NCT03833661, and NCT04066491), received an intravenous infusion of bintrafusp alfa at the dose specified based upon the subject's parent protocol once every 2 weeks or 2400 mg once every 3 weeks until disease progression, death, unacceptable toxicity, or study withdrawal. Subjects who entered the rollover study after discontinuation of treatment in a parent study received bintrafusp alfa at a dose of either 1200 or 2400 mg once every 2 weeks or 2400 mg once every 3 weeks until disease progression, death, unacceptable toxicity, or study withdrawal.

Arm type	Experimental
Investigational medicinal product name	Bintrafusp alfa
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects who are continuing treatment with bintrafusp alfa and were previously assigned to a bintrafusp alfa dose based on body weight which is (i.e.) milligrams per kilogram (mg/kg) dose in a parent protocol, received an intravenous infusion of bintrafusp alfa at the dose specified based upon the subject's parent protocol once every 2 week or, 2400 mg once every 3 weeks. Subjects who are

entering the rollover study after discontinuation of treatment in a parent study received bintrafusp alfa at a dose of either 1200 or 2400 mg once every 2 weeks or 2400 mg once every 3 weeks until confirmed disease progression, death, unacceptable toxicity or study withdrawal.

Number of subjects in period 1^[1]	Biliary Tract Cancer	Non-small Cell Lung Cancer	Cervical Cancer
Started	10	5	3
Completed	4	3	2
Not completed	6	2	1
Adverse event, serious fatal	1	2	1
Stop By Sponsor	2	-	-
End Of Study Due To Suspension Of Drug Supply	2	-	-
sponsor-requested study withdrawal	1	-	-

Number of subjects in period 1^[1]	Other (Colorectal cancer, Glioblastoma, Melanoma)
Started	4
Completed	1
Not completed	3
Adverse event, serious fatal	2
Stop By Sponsor	1
End Of Study Due To Suspension Of Drug Supply	-
sponsor-requested study withdrawal	-

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: There was one subject who was enrolled in the study but did not receive any study treatment.

Baseline characteristics

Reporting groups

Reporting group title	Biliary Tract Cancer
-----------------------	----------------------

Reporting group description:

Subjects with biliary tract cancer, who were continuing treatment with bintrafusp alfa and were previously assigned to a bintrafusp alfa dose based on body weight (i.e., milligrams per kilogram (mg/kg) dose) in a parent protocol (NCT02517398, NCT02699515, NCT04246489, NCT03840915, NCT03631706, NCT04551950, NCT03833661, and NCT04066491), received an intravenous infusion of bintrafusp alfa at the dose specified based upon the subjects parent protocol once every 2 weeks or 2400 mg once every 3 weeks until disease progression, death, unacceptable toxicity, or study withdrawal. Subjects who entered the rollover study after discontinuation of treatment in a parent study received bintrafusp alfa at a dose of either 1200 or 2400 mg once every 2 weeks or 2400 mg once every 3 weeks until disease progression, death, unacceptable toxicity, or study withdrawal.

Reporting group title	Non-small Cell Lung Cancer
-----------------------	----------------------------

Reporting group description:

Subjects with Non small cell lung cancer, who were continuing treatment with bintrafusp alfa and were previously assigned to a bintrafusp alfa dose based on body weight i.e., mg/kg dose in a parent protocol (NCT02517398, NCT02699515, NCT04246489, NCT03840915, NCT03631706, NCT04551950, NCT03833661, and NCT04066491), received an intravenous infusion of bintrafusp alfa at the dose specified based upon the subjects parent protocol once every 2 weeks or 2400 mg once every 3 weeks until disease progression, death, unacceptable toxicity, or study withdrawal. Subjects who entered the rollover study after discontinuation of treatment in a parent study received bintrafusp alfa at a dose of either 1200 or 2400 mg once every 2 weeks or 2400 mg once every 3 weeks until disease progression, death, unacceptable toxicity, or study withdrawal.

Reporting group title	Cervical Cancer
-----------------------	-----------------

Reporting group description:

Subjects with cervical cancer, who were continuing treatment with bintrafusp alfa and were previously assigned to a bintrafusp alfa dose based on body weight i.e., mg/kg dose in a parent protocol (NCT02517398, NCT02699515, NCT04246489, NCT03840915, NCT03631706, NCT04551950, NCT03833661, and NCT04066491), received an intravenous infusion of bintrafusp alfa at the dose specified based upon the subject's parent protocol once every 2 weeks or 2400 mg once every 3 weeks until disease progression, death, unacceptable toxicity, or study withdrawal. Subjects who entered the rollover study after discontinuation of treatment in a parent study received bintrafusp alfa at a dose of either 1200 or 2400 mg once every 2 weeks or 2400 mg once every 3 weeks until disease progression, death, unacceptable toxicity, or study withdrawal.

Reporting group title	Other (Colorectal cancer, Glioblastoma, Melanoma)
-----------------------	---

Reporting group description:

Subjects with Other (Colorectal cancer, Glioblastoma, Melanoma) who were continuing treatment with bintrafusp alfa and were previously assigned to a bintrafusp alfa dose based on body weight i.e., mg/kg dose in a parent protocol (NCT02517398, NCT02699515, NCT04246489, NCT03840915, NCT03631706, NCT04551950, NCT03833661, and NCT04066491), received an intravenous infusion of bintrafusp alfa at the dose specified based upon the subject's parent protocol once every 2 weeks or 2400 mg once every 3 weeks until disease progression, death, unacceptable toxicity, or study withdrawal. Subjects who entered the rollover study after discontinuation of treatment in a parent study received bintrafusp alfa at a dose of either 1200 or 2400 mg once every 2 weeks or 2400 mg once every 3 weeks until disease progression, death, unacceptable toxicity, or study withdrawal.

Reporting group values	Biliary Tract Cancer	Non-small Cell Lung Cancer	Cervical Cancer
Number of subjects	10	5	3
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0

Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	6	3	3
From 65-84 years	4	2	0
85 years and over	0	0	0
Age Continuous			
Units: Years			
arithmetic mean	59	63	48
standard deviation	± 10.3	± 7.4	± 14.4
Sex: Female, Male			
Units: subjects			
Female	3	2	3
Male	7	3	0
Ethnicity			
Units: Subjects			
Hispanic or Latino	0	0	0
Not Hispanic or Latino	9	5	3
Missing	0	0	0
Not collected	1	0	0
Race			
Units: Subjects			
Asian	10	1	2
American Indian or Alaska Native	0	0	0
Black or African American	0	1	0
Native Hawaiian or Other Pacific Islander	0	0	0
White	0	3	1
Other	0	0	0
Missing	0	0	0

Reporting group values	Other (Colorectal cancer, Glioblastoma, Melanoma)	Total	
Number of subjects	4	22	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	3	15	
From 65-84 years	1	7	
85 years and over	0	0	
Age Continuous			
Units: Years			
arithmetic mean	52		
standard deviation	± 16.9	-	

Sex: Female, Male			
Units: subjects			
Female	1	9	
Male	3	13	
Ethnicity			
Units: Subjects			
Hispanic or Latino	0	0	
Not Hispanic or Latino	3	20	
Missing	0	0	
Not collected	1	2	
Race			
Units: Subjects			
Asian	1	14	
American Indian or Alaska Native	0	0	
Black or African American	0	1	
Native Hawaiian or Other Pacific Islander	0	0	
White	3	7	
Other	0	0	
Missing	0	0	

End points

End points reporting groups

Reporting group title	Biliary Tract Cancer
Reporting group description:	
Subjects with biliary tract cancer, who were continuing treatment with bintrafusp alfa and were previously assigned to a bintrafusp alfa dose based on body weight (i.e., milligrams per kilogram (mg/kg) dose) in a parent protocol (NCT02517398, NCT02699515, NCT04246489, NCT03840915, NCT03631706, NCT04551950, NCT03833661, and NCT04066491), received an intravenous infusion of bintrafusp alfa at the dose specified based upon the subjects parent protocol once every 2 weeks or 2400 mg once every 3 weeks until disease progression, death, unacceptable toxicity, or study withdrawal. Subjects who entered the rollover study after discontinuation of treatment in a parent study received bintrafusp alfa at a dose of either 1200 or 2400 mg once every 2 weeks or 2400 mg once every 3 weeks until disease progression, death, unacceptable toxicity, or study withdrawal.	
Reporting group title	Non-small Cell Lung Cancer
Reporting group description:	
Subjects with Non small cell lung cancer, who were continuing treatment with bintrafusp alfa and were previously assigned to a bintrafusp alfa dose based on body weight i.e., mg/kg dose in a parent protocol (NCT02517398, NCT02699515, NCT04246489, NCT03840915, NCT03631706, NCT04551950, NCT03833661, and NCT04066491), received an intravenous infusion of bintrafusp alfa at the dose specified based upon the subjects parent protocol once every 2 weeks or 2400 mg once every 3 weeks until disease progression, death, unacceptable toxicity, or study withdrawal. Subjects who entered the rollover study after discontinuation of treatment in a parent study received bintrafusp alfa at a dose of either 1200 or 2400 mg once every 2 weeks or 2400 mg once every 3 weeks until disease progression, death, unacceptable toxicity, or study withdrawal.	
Reporting group title	Cervical Cancer
Reporting group description:	
Subjects with cervical cancer, who were continuing treatment with bintrafusp alfa and were previously assigned to a bintrafusp alfa dose based on body weight i.e., mg/kg dose in a parent protocol (NCT02517398, NCT02699515, NCT04246489, NCT03840915, NCT03631706, NCT04551950, NCT03833661, and NCT04066491), received an intravenous infusion of bintrafusp alfa at the dose specified based upon the subject's parent protocol once every 2 weeks or 2400 mg once every 3 weeks until disease progression, death, unacceptable toxicity, or study withdrawal. Subjects who entered the rollover study after discontinuation of treatment in a parent study received bintrafusp alfa at a dose of either 1200 or 2400 mg once every 2 weeks or 2400 mg once every 3 weeks until disease progression, death, unacceptable toxicity, or study withdrawal.	
Reporting group title	Other (Colorectal cancer, Glioblastoma, Melanoma)
Reporting group description:	
Subjects with Other (Colorectal cancer, Glioblastoma, Melanoma) who were continuing treatment with bintrafusp alfa and were previously assigned to a bintrafusp alfa dose based on body weight i.e., mg/kg dose in a parent protocol (NCT02517398, NCT02699515, NCT04246489, NCT03840915, NCT03631706, NCT04551950, NCT03833661, and NCT04066491), received an intravenous infusion of bintrafusp alfa at the dose specified based upon the subject's parent protocol once every 2 weeks or 2400 mg once every 3 weeks until disease progression, death, unacceptable toxicity, or study withdrawal. Subjects who entered the rollover study after discontinuation of treatment in a parent study received bintrafusp alfa at a dose of either 1200 or 2400 mg once every 2 weeks or 2400 mg once every 3 weeks until disease progression, death, unacceptable toxicity, or study withdrawal.	

Primary: Number of Subjects with Treatment Emergent Adverse events (TEAEs) and Treatment Related AEs (TRAEs)

End point title	Number of Subjects with Treatment Emergent Adverse events (TEAEs) and Treatment Related AEs (TRAEs) ^[1]
End point description:	
An AE is any untoward medical occurrence in a subject or clinical study subject, temporarily associated with the use of study intervention, whether considered related to the study intervention or not. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. TEAEs were defined as AEs emerging or worsening after start of treatment until 30 days after end of treatment. TRAE was defined as any AE considered as related to study treatment. Safety analysis set	

included all participants who received at least one dose of study intervention in the Rollover study.

End point type	Primary
----------------	---------

End point timeframe:

Baseline in parent study (NCT02517398, NCT02699515, NCT04246489, NCT03840915, NCT03631706, NCT04551950, NCT03833661 and NCT04066491) upto end of current rollover study (approximately assessed upto a maximum of 9 years, 6 months, 22 days)

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical and comparison analysis were performed in single arm for this endpoint.

End point values	Biliary Tract Cancer	Non-small Cell Lung Cancer	Cervical Cancer	Other (Colorectal cancer, Glioblastoma, Melanoma)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	5	3	4
Units: subjects				
TEAEs	10	5	3	4
TRAEs	10	5	3	4

Statistical analyses

No statistical analyses for this end point

Secondary: Overall Survival (OS)

End point title	Overall Survival (OS)
-----------------	-----------------------

End point description:

OS was defined as the time from study day 1 in parent study to the date of death due to any cause. The overall survival was analyzed by using the Kaplan-Meier method. Full Analysis Set (FAS) included all participants who received at least one dose of study intervention in the Rollover study.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline in parent study (NCT02517398, NCT02699515, NCT04246489, NCT03840915, NCT03631706, NCT04551950, NCT03833661 and NCT04066491) upto end of current rollover study (approximately assessed upto a maximum of 9 years, 6 months, 22 days)

End point values	Biliary Tract Cancer	Non-small Cell Lung Cancer	Cervical Cancer	Other (Colorectal cancer, Glioblastoma, Melanoma)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10 ^[2]	5 ^[3]	3 ^[4]	4 ^[5]
Units: months				
median (confidence interval 90%)	99999 (99999 to 999999)	99999 (99999 to 99999)	99999 (99999 to 99999)	99999 (99999 to 99999)

Notes:

[2] - 99999=No observation; median and CI not reached, low number of events

[3] - 99999=No observation;median and CI not reached, low number of events

[4] - 99999=No observation;median and CI not reached, low number of events

[5] - 99999=No observation;median and CI not reached, low number of events

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From the first dose of study intervention in the Rollover study to the last administration of study intervention + 30 days (approximately 39 months and 21 days)

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	27.1
--------------------	------

Reporting groups

Reporting group title	Biliary Tract Cancer
-----------------------	----------------------

Reporting group description:

Subjects with biliary tract cancer, who were continuing treatment with bintrafusp alfa and were previously assigned to a bintrafusp alfa dose based on body weight (i.e., milligrams per kilogram (mg/kg) dose) in a parent protocol (NCT02517398, NCT02699515, NCT04246489, NCT03840915, NCT03631706, NCT04551950, NCT03833661, and NCT04066491), received an intravenous infusion of bintrafusp alfa at the dose specified based upon the subjects parent protocol once every 2 weeks or 2400 mg once every 3 weeks until disease progression, death, unacceptable toxicity, or study withdrawal. Subjects who entered the rollover study after discontinuation of treatment in a parent study received bintrafusp alfa at a dose of either 1200 or 2400 mg once every 2 weeks or 2400 mg once every 3 weeks until disease progression, death, unacceptable toxicity, or study withdrawal.

Reporting group title	Cervical Cancer
-----------------------	-----------------

Reporting group description:

Subjects with cervical cancer, who were continuing treatment with bintrafusp alfa and were previously assigned to a bintrafusp alfa dose based on body weight i.e., mg/kg dose in a parent protocol (NCT02517398, NCT02699515, NCT04246489, NCT03840915, NCT03631706, NCT04551950, NCT03833661, and NCT04066491), received an intravenous infusion of bintrafusp alfa at the dose specified based upon the subjects parent protocol once every 2 weeks or 2400 mg once every 3 weeks until disease progression, death, unacceptable toxicity, or study withdrawal. Subjects who entered the rollover study after discontinuation of treatment in a parent study received bintrafusp alfa at a dose of either 1200 or 2400 mg once every 2 weeks or 2400 mg once every 3 weeks until disease progression, death, unacceptable toxicity, or study withdrawal.

Reporting group title	Non-small Cell Lung Cancer
-----------------------	----------------------------

Reporting group description:

Subjects with Non small cell lung cancer, who were continuing treatment with bintrafusp alfa and were previously assigned to a bintrafusp alfa dose based on body weight i.e., mg/kg dose in a parent protocol (NCT02517398, NCT02699515, NCT04246489, NCT03840915, NCT03631706, NCT04551950, NCT03833661, and NCT04066491), received an intravenous infusion of bintrafusp alfa at the dose specified based upon the subjects parent protocol once every 2 weeks or 2400 mg once every 3 weeks until disease progression, death, unacceptable toxicity, or study withdrawal. Subjects who entered the rollover study after discontinuation of treatment in a parent study received bintrafusp alfa at a dose of either 1200 or 2400 mg once every 2 weeks or 2400 mg once every 3 weeks until disease progression, death, unacceptable toxicity, or study withdrawal.

Reporting group title	Other (Colorectal cancer, Glioblastoma, Melanoma)
-----------------------	---

Reporting group description:

Subjects with Other (Colorectal cancer, Glioblastoma, Melanoma) who were continuing treatment with bintrafusp alfa and were previously assigned to a bintrafusp alfa dose based on body weight i.e., mg/kg dose in a parent protocol (NCT02517398, NCT02699515, NCT04246489, NCT03840915, NCT03631706, NCT04551950, NCT03833661, and NCT04066491), received an intravenous infusion of bintrafusp alfa at the dose specified based upon the subjects parent protocol once every 2 weeks or 2400 mg once every 3 weeks until disease progression, death, unacceptable toxicity, or study withdrawal. Subjects who entered the rollover study after discontinuation of treatment in a parent study received bintrafusp alfa at a dose of either 1200 or 2400 mg once every 2 weeks or 2400 mg once every 3 weeks until disease progression, death, unacceptable toxicity, or study withdrawal.

Serious adverse events	Biliary Tract Cancer	Cervical Cancer	Non-small Cell Lung Cancer
Total subjects affected by serious adverse events			
subjects affected / exposed	3 / 10 (30.00%)	1 / 3 (33.33%)	4 / 5 (80.00%)
number of deaths (all causes)	1	1	2
number of deaths resulting from adverse events			
Investigations			
Blood creatinine increased			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebral ischaemia			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Death			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Disease progression			

alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Gastrointestinal disorders			
Diaphragmatic hernia			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Interstitial lung disease			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Rash			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Abscess			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			

alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronavirus infection			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	0 / 10 (0.00%)	1 / 3 (33.33%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Other (Colorectal cancer, Glioblastoma, Melanoma)		
Total subjects affected by serious adverse events			

subjects affected / exposed number of deaths (all causes) number of deaths resulting from adverse events	2 / 4 (50.00%) 2		
Investigations Blood creatinine increased alternative dictionary used: MedDRA 27.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 4 (0.00%) 0 / 0 0 / 0		
Nervous system disorders Cerebral ischaemia alternative dictionary used: MedDRA 27.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 4 (25.00%) 0 / 1 0 / 0		
Seizure alternative dictionary used: MedDRA 27.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 4 (25.00%) 0 / 1 0 / 0		
Blood and lymphatic system disorders Anaemia alternative dictionary used: MedDRA 27.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 4 (0.00%) 0 / 0 0 / 0		
General disorders and administration site conditions Death alternative dictionary used: MedDRA 27.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 4 (0.00%) 0 / 0 0 / 0		
Disease progression alternative dictionary used: MedDRA 27.1			

subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Diaphragmatic hernia			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Interstitial lung disease			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pulmonary embolism			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	1 / 4 (25.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Skin and subcutaneous tissue disorders			
Rash			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Abscess			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cellulitis			
alternative dictionary used: MedDRA 27.1			

subjects affected / exposed	1 / 4 (25.00%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Coronavirus infection				
alternative dictionary used: MedDRA 27.1				
subjects affected / exposed	0 / 4 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Influenza				
alternative dictionary used: MedDRA 27.1				
subjects affected / exposed	1 / 4 (25.00%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Pneumonia				
alternative dictionary used: MedDRA 27.1				
subjects affected / exposed	0 / 4 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Sepsis				
alternative dictionary used: MedDRA 27.1				
subjects affected / exposed	0 / 4 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Septic shock				
alternative dictionary used: MedDRA 27.1				
subjects affected / exposed	0 / 4 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Biliary Tract Cancer	Cervical Cancer	Non-small Cell Lung Cancer
Total subjects affected by non-serious adverse events			
subjects affected / exposed	8 / 10 (80.00%)	3 / 3 (100.00%)	3 / 5 (60.00%)
Vascular disorders			
Hypotension			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	2
General disorders and administration site conditions			
Asthenia			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	2 / 5 (40.00%)
occurrences (all)	2	0	14
Axillary pain			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	0 / 10 (0.00%)	1 / 3 (33.33%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
Fatigue			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	2 / 5 (40.00%)
occurrences (all)	1	0	5
Hernia			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Influenza like illness			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	1 / 10 (10.00%)	1 / 3 (33.33%)	0 / 5 (0.00%)
occurrences (all)	1	1	0
Localised oedema			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Pyrexia			
alternative dictionary used: MedDRA 27.1			

subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 3 (33.33%) 1	0 / 5 (0.00%) 0
Immune system disorders Seasonal allergy alternative dictionary used: MedDRA 27.1 subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 3 (33.33%) 1	0 / 5 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Cough alternative dictionary used: MedDRA 27.1 subjects affected / exposed occurrences (all) Dyspnoea alternative dictionary used: MedDRA 27.1 subjects affected / exposed occurrences (all) Pneumonitis alternative dictionary used: MedDRA 27.1 subjects affected / exposed occurrences (all) Productive cough alternative dictionary used: MedDRA 27.1 subjects affected / exposed occurrences (all) Pulmonary embolism alternative dictionary used: MedDRA 27.1 subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1 0 / 10 (0.00%) 0 1 / 10 (10.00%) 1 0 / 10 (0.00%) 0	0 / 3 (0.00%) 0 0 / 3 (0.00%) 0 0 / 3 (0.00%) 0 0 / 3 (0.00%) 0	1 / 5 (20.00%) 4 1 / 5 (20.00%) 2 0 / 5 (0.00%) 0 0 / 5 (0.00%) 0
Psychiatric disorders Insomnia alternative dictionary used: MedDRA 27.1 subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 3 (0.00%) 0	0 / 5 (0.00%) 0
Investigations			

Bilirubin conjugated increased alternative dictionary used: MedDRA 27.1 subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 3 (33.33%) 1	0 / 5 (0.00%) 0
Blood bilirubin increased alternative dictionary used: MedDRA 27.1 subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 3 (0.00%) 0	1 / 5 (20.00%) 1
Blood creatine phosphokinase increased alternative dictionary used: MedDRA 27.1 subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 3 (0.00%) 0	0 / 5 (0.00%) 0
Blood creatinine increased alternative dictionary used: MedDRA 27.1 subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 3 (0.00%) 0	1 / 5 (20.00%) 2
Lymphocyte count decreased alternative dictionary used: MedDRA 27.1 subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 3 (33.33%) 4	0 / 5 (0.00%) 0
Neutrophil count decreased alternative dictionary used: MedDRA 27.1 subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 3 (0.00%) 0	0 / 5 (0.00%) 0
Platelet count decreased alternative dictionary used: MedDRA 27.1 subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 3 (33.33%) 4	0 / 5 (0.00%) 0
Weight decreased alternative dictionary used: MedDRA 27.1 subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 3 (0.00%) 0	1 / 5 (20.00%) 1
Weight increased alternative dictionary used: MedDRA 27.1			

subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 3 (33.33%) 1	0 / 5 (0.00%) 0
Injury, poisoning and procedural complications Ankle fracture alternative dictionary used: MedDRA 27.1 subjects affected / exposed occurrences (all) Thermal burn alternative dictionary used: MedDRA 27.1 subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1 0 / 10 (0.00%) 0	0 / 3 (0.00%) 0 0 / 3 (0.00%) 0	0 / 5 (0.00%) 0 0 / 5 (0.00%) 0
Nervous system disorders Dizziness alternative dictionary used: MedDRA 27.1 subjects affected / exposed occurrences (all) Dysaesthesia alternative dictionary used: MedDRA 27.1 subjects affected / exposed occurrences (all) Headache alternative dictionary used: MedDRA 27.1 subjects affected / exposed occurrences (all) Somnolence alternative dictionary used: MedDRA 27.1 subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1 0 / 10 (0.00%) 0 0 / 10 (0.00%) 0 0 / 10 (0.00%) 0	1 / 3 (33.33%) 1 0 / 3 (0.00%) 0 1 / 3 (33.33%) 1 0 / 3 (0.00%) 0	0 / 5 (0.00%) 0 0 / 5 (0.00%) 0 1 / 5 (20.00%) 1 0 / 5 (0.00%) 0
Blood and lymphatic system disorders Anaemia alternative dictionary used: MedDRA 27.1 subjects affected / exposed occurrences (all)	3 / 10 (30.00%) 4	1 / 3 (33.33%) 1	2 / 5 (40.00%) 18
Ear and labyrinth disorders			

<p>Ear swelling</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 10 (10.00%)</p> <p>1</p>	<p>0 / 3 (0.00%)</p> <p>0</p>	<p>0 / 5 (0.00%)</p> <p>0</p>
<p>Vertigo</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 10 (0.00%)</p> <p>0</p>	<p>1 / 3 (33.33%)</p> <p>1</p>	<p>0 / 5 (0.00%)</p> <p>0</p>
<p>Gastrointestinal disorders</p> <p>Abdominal pain</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Constipation</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Dental caries</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Diarrhoea</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Dry mouth</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Melaena</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Nausea</p> <p>alternative dictionary used: MedDRA 27.1</p>	<p>0 / 10 (0.00%)</p> <p>0</p> <p>1 / 10 (10.00%)</p> <p>1</p> <p>0 / 10 (0.00%)</p> <p>0</p> <p>1 / 10 (10.00%)</p> <p>1</p> <p>1 / 10 (10.00%)</p> <p>1</p> <p>1 / 10 (10.00%)</p> <p>1</p>	<p>1 / 3 (33.33%)</p> <p>1</p> <p>0 / 3 (0.00%)</p> <p>0</p> <p>0 / 3 (0.00%)</p> <p>0</p> <p>0 / 3 (0.00%)</p> <p>0</p> <p>0 / 3 (0.00%)</p> <p>0</p>	<p>0 / 5 (0.00%)</p> <p>0</p> <p>0 / 5 (0.00%)</p> <p>0</p> <p>0 / 5 (0.00%)</p> <p>0</p> <p>0 / 5 (0.00%)</p> <p>0</p> <p>0 / 5 (0.00%)</p> <p>0</p>

subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Stomatitis			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	0 / 10 (0.00%)	2 / 3 (66.67%)	0 / 5 (0.00%)
occurrences (all)	0	4	0
Skin and subcutaneous tissue disorders			
Alopecia			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Blister			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Decubitus ulcer			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Dermatitis			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Dermatitis acneiform			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	0 / 10 (0.00%)	1 / 3 (33.33%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
Dry skin			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	0 / 10 (0.00%)	1 / 3 (33.33%)	1 / 5 (20.00%)
occurrences (all)	0	1	1
Eczema			
alternative dictionary used: MedDRA 27.1			

subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Erythema			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Pruritus			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	3 / 10 (30.00%)	0 / 3 (0.00%)	3 / 5 (60.00%)
occurrences (all)	3	0	10
Rash			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	2 / 10 (20.00%)	1 / 3 (33.33%)	0 / 5 (0.00%)
occurrences (all)	2	2	0
Skin mass			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Urticaria			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	0 / 10 (0.00%)	1 / 3 (33.33%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
Bursitis			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Neck pain			
alternative dictionary used: MedDRA 27.1			

subjects affected / exposed	0 / 10 (0.00%)	1 / 3 (33.33%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
Pain in extremity			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	3
Infections and infestations			
Abscess			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	2
Carbuncle			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
COVID-19			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	2 / 10 (20.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	2	0	0
Cystitis			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Furuncle			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Influenza			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Nasopharyngitis			
alternative dictionary used: MedDRA 27.1			

subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Onychomycosis			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Pneumonia			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Rash pustular			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Tinea infection			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	1 / 10 (10.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Urinary tract infection			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Metabolism and nutrition disorders			
Decreased appetite			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	0 / 10 (0.00%)	2 / 3 (66.67%)	1 / 5 (20.00%)
occurrences (all)	0	2	1
Hyperlipidaemia			
alternative dictionary used: MedDRA 27.1			

subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Hypoalbuminaemia			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	3
Hypomagnesaemia			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	0 / 10 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	2

Non-serious adverse events	Other (Colorectal cancer, Glioblastoma, Melanoma)		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	3 / 4 (75.00%)		
Vascular disorders			
Hypotension			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
General disorders and administration site conditions			
Asthenia			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Axillary pain			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Fatigue			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Hernia			
alternative dictionary used: MedDRA 27.1			

<p>subjects affected / exposed</p> <p>0 / 4 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> <p>Influenza like illness</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>0 / 4 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> <p>Localised oedema</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>0 / 4 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> <p>Pyrexia</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>1 / 4 (25.00%)</p> <p>occurrences (all)</p> <p>2</p>			
<p>Immune system disorders</p> <p>Seasonal allergy</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>0 / 4 (0.00%)</p> <p>occurrences (all)</p> <p>0</p>			
<p>Respiratory, thoracic and mediastinal disorders</p> <p>Cough</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>1 / 4 (25.00%)</p> <p>occurrences (all)</p> <p>1</p> <p>Dyspnoea</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>0 / 4 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> <p>Pneumonitis</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>0 / 4 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> <p>Productive cough</p> <p>alternative dictionary used: MedDRA 27.1</p>			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Pulmonary embolism</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 4 (0.00%)</p> <p>0</p> <p>1 / 4 (25.00%)</p> <p>1</p>		
<p>Psychiatric disorders</p> <p>Insomnia</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 4 (25.00%)</p> <p>1</p>		
<p>Investigations</p> <p>Bilirubin conjugated increased</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Blood bilirubin increased</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Blood creatine phosphokinase increased</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Blood creatinine increased</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Lymphocyte count decreased</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Neutrophil count decreased</p> <p>alternative dictionary used: MedDRA 27.1</p>	<p>0 / 4 (0.00%)</p> <p>0</p> <p>0 / 4 (0.00%)</p> <p>0</p> <p>1 / 4 (25.00%)</p> <p>3</p> <p>0 / 4 (0.00%)</p> <p>0</p> <p>0 / 4 (0.00%)</p> <p>0</p>		

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Platelet count decreased</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Weight decreased</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Weight increased</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 4 (0.00%)</p> <p>0</p> <p>0 / 4 (0.00%)</p> <p>0</p> <p>0 / 4 (0.00%)</p> <p>0</p> <p>0 / 4 (0.00%)</p> <p>0</p>		
<p>Injury, poisoning and procedural complications</p> <p>Ankle fracture</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Thermal burn</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 4 (0.00%)</p> <p>0</p> <p>1 / 4 (25.00%)</p> <p>1</p>		
<p>Nervous system disorders</p> <p>Dizziness</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Dysaesthesia</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Headache</p> <p>alternative dictionary used: MedDRA 27.1</p>	<p>0 / 4 (0.00%)</p> <p>0</p> <p>1 / 4 (25.00%)</p> <p>1</p>		

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Somnolence</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 4 (25.00%)</p> <p>1</p> <p>1 / 4 (25.00%)</p> <p>1</p>		
<p>Blood and lymphatic system disorders</p> <p>Anaemia</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 4 (0.00%)</p> <p>0</p>		
<p>Ear and labyrinth disorders</p> <p>Ear swelling</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Vertigo</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 4 (0.00%)</p> <p>0</p> <p>0 / 4 (0.00%)</p> <p>0</p>		
<p>Gastrointestinal disorders</p> <p>Abdominal pain</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Constipation</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Dental caries</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Diarrhoea</p> <p>alternative dictionary used: MedDRA 27.1</p>	<p>0 / 4 (0.00%)</p> <p>0</p> <p>0 / 4 (0.00%)</p> <p>0</p> <p>1 / 4 (25.00%)</p> <p>1</p>		

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Dry mouth</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Melaena</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Nausea</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Stomatitis</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 4 (25.00%)</p> <p>1</p> <p>0 / 4 (0.00%)</p> <p>0</p> <p>0 / 4 (0.00%)</p> <p>0</p> <p>0 / 4 (0.00%)</p> <p>0</p> <p>0 / 4 (0.00%)</p> <p>0</p>		
<p>Skin and subcutaneous tissue disorders</p> <p>Alopecia</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Blister</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Decubitus ulcer</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Dermatitis</p> <p>alternative dictionary used: MedDRA 27.1</p>	<p>0 / 4 (0.00%)</p> <p>0</p> <p>0 / 4 (0.00%)</p> <p>0</p> <p>0 / 4 (0.00%)</p> <p>0</p>		

subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Dermatitis acneiform			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	1 / 4 (25.00%)		
occurrences (all)	1		
Dry skin			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Eczema			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Erythema			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	1 / 4 (25.00%)		
occurrences (all)	1		
Pruritus			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	1 / 4 (25.00%)		
occurrences (all)	1		
Rash			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	1 / 4 (25.00%)		
occurrences (all)	1		
Skin mass			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Urticaria			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	1 / 4 (25.00%)		
occurrences (all)	1		

<p>Musculoskeletal and connective tissue disorders</p> <p>Arthralgia</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>0 / 4 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> <p>Bursitis</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>1 / 4 (25.00%)</p> <p>occurrences (all)</p> <p>1</p> <p>Neck pain</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>0 / 4 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> <p>Pain in extremity</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>0 / 4 (0.00%)</p> <p>occurrences (all)</p> <p>0</p>			
<p>Infections and infestations</p> <p>Abscess</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>0 / 4 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> <p>Carbuncle</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>1 / 4 (25.00%)</p> <p>occurrences (all)</p> <p>1</p> <p>COVID-19</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>1 / 4 (25.00%)</p> <p>occurrences (all)</p> <p>3</p> <p>Cystitis</p> <p>alternative dictionary used: MedDRA 27.1</p> <p>subjects affected / exposed</p> <p>0 / 4 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> <p>Furuncle</p>			

alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Influenza			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	1 / 4 (25.00%)		
occurrences (all)	1		
Nasopharyngitis			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	1 / 4 (25.00%)		
occurrences (all)	2		
Onychomycosis			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Pneumonia			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Rash pustular			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	0 / 4 (0.00%)		
occurrences (all)	0		
Tinea infection			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	1 / 4 (25.00%)		
occurrences (all)	1		
Upper respiratory tract infection			
alternative dictionary used: MedDRA 27.1			
subjects affected / exposed	1 / 4 (25.00%)		
occurrences (all)	2		
Urinary tract infection			
alternative dictionary used: MedDRA 27.1			

subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 2		
Metabolism and nutrition disorders			
Decreased appetite alternative dictionary used: MedDRA 27.1 subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0		
Hyperlipidaemia alternative dictionary used: MedDRA 27.1 subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1		
Hypoalbuminaemia alternative dictionary used: MedDRA 27.1 subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 0		
Hypomagnesaemia alternative dictionary used: MedDRA 27.1 subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported